Modeling the impact of genetic screening technologies on healthcare: Theoretical model for asthma in children

Molecular Diagnosis and Therapy

Volumn 11, Issue 5, 2007, Pages 313-323

  Gutiérrez De Mesa, Emma ^a   Hidalgo, Ignacio ^a   Christidis, Panayotis ^a   Ciscar, Juan Carlos ^a   Vegas, Eva ^b   Ibarreta, Dolores ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b Servicio Madrileño de Salud Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

Author keywords

Asthma, prevention; Cost effectiveness; Genotyping; Screening

Indexed keywords

ARTICLE; ASTHMA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PROCEDURES; GENETIC SCREENING; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION; WHEEZING;

EID: 35548971236     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256252     Document Type: Article

References (77)

1. Arenas-Guzman R, Tosti A, Hay R, et al. Pharmacoeconomics: an aid to better decision-making. J Eur Acad Dermatol Venereol 2005; 19 Suppl. 1: 34-9
2. Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature, 2003; 422 (6934): 835-47
3. Eurostat, Health statistics. Key data on health 2002. Data 1970-2001, 2004 [online]. Available from URL: http://ec.europa.eu/health/index_en.htm [Accessed 2007 Oct 15]
4. European Respiratory Society. European lung white book. Lausanne: European Respiratory Society Publication Department, 2003
5. European Commission. The social situation in the European Union in 2003. Luxembourg: European Commission Publications, 2004
6. van den Akker-van Marle ME, Bruil J, Detmar SB. Evaluation of cost of disease: assessing the burden to society of asthma in children in the European Union [report 21]. Delft: TNO, 2004
7. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet 1998; 351: 1225-32
8. European Community Respiratory Health Survey (ECRHS). Variations in the prevalence of respiratory symptoms, self reported asthma attacks, and use of asthma medication in the European Community. Respiratory Health Survey. Eur Respir J 1996; 9: 687-95
9. Aubier M, Neukirch F, Annesi-Maesano I. Epidemiology of asthma and allergies: the prevalence of allergies increases worldwide, and asthma has reached his highest-ever prevalence in Europe: why? Bull Acad Natl Med 2005; 189 (7): 1419-34; discussion 1434
10. NIH. Global strategy for asthma management and prevention. Bethesda (MD): National Heart, Lung, and Blood Institute, 2002: 176
11. Gerth van Wijk R. Allergy: a global problem: quality of life. Allergy 2002; 57 (12): 1097-110
12. European Environment Agency and the Joint Research Centre (JRC) of the European Commission. Environment and health. EEA Report No 10/2005. Luxembourg: European Commission Publications, 2005
13. Sennhauser FH, Braun-Fahrlander C, Wildhaber JH. The burden of asthma in children: a European perspective. Paediatr Respir Rev 2005; 6 (1): 2-7
14. Blumenthal J, Blumenthal M. Genetics of asthma. Med Clin North Am 2002; 86 (50): 937-50
15. King ME, Mannino DM, Holguin F. Risk factors for asthma incidence: a review of recent prospective evidence. Panminerva Med 2004; 46 (2): 97-110
16. Melen E, Wickman M, Nordvall SL, et al. Influence of early and current environmental exposure factors on sensitization and outcome of asthma in pre-school children. Allergy 2001; 56 (7): 646-52
17. Brussee JE, Smit HA, van Strien RT, et al. Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years. J Allergy Clin Immunol 2005; 115 (5): 946-52
18. Lewis TC, Robins TG, Dvonch JT, et al. Air pollution-associated changes in lung function among asthmatic children in Detroit. Environ Health Perspect 2005; 113 (8): 1068-75
19. Willers SM, Brunekreef B, Oldenwening M, et al. Gas cooking, kitchen ventilation, and asthma, allergic symptoms and sensitization in young children: the PIAMA study. Allergy 2006; 61 (5): 563-8
20. Carroll W. Asthma genetics: pitfalls and triumphs. Paediatr Respir Rev 2005; 6 (1): 68-74
21. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3 (5): 440-3
22. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun 2006; 7 (2): 95-100
23. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332 (3): 133-8
24. Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001; 108 (5): 720-5
25. Holgate ST. A need for circulating biomarkers of severe persistent asthma and its treatment. Clin Exp Allergy 2006; 36 (11): 1355-6
26. Jongepier H, Boezen HM, Dijkastra A, et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004; 34 (5): 757-60
27. Noguchi E, Ohtsuki Y, Tokunaga K, et al. ADAM33 polymorphisms are associated with asthma susceptibility in a Japanese population. Clin Exp Allergy 2006; 36 (5): 602-8
28. Kedda MA, Duffy DL, Bradley B, et al. ADAM33 haplotypes are associated with asthma in a large Australian population. Eur J Hum Genet 2006; 14 (9): 1027-36
29. van Diemen CC, Postma DS, Vonk JM, et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005; 172 (3): 329-33
30. Simpson A, Maniatis N, Jury F, et al. Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am J Respir Crit Care Med 2005; 172 (1): 55-60
31. Liu AH. Consider the child: how early should we treat? J Allergy Clin Immunol 2004; 113 (1 Suppl.): S19-24
32. Larsen GL, Kang JK, Guilbert T, et al. Assessing respiratory function in young children: developmental considerations. J Allergy Clin Immunol 2005; 115 (4): 657-66
33. Van Eerdewegh P, Little RD, Duguis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418 (6896): 426-30
34. Hirota T, Hasegawa K, Obara K, et al. Association between ADAM33 polymorphisms and adult asthma in the Japanese population. Clin Exp Allergy 2006; 36 (7): 884-91
35. Howard TD, Postma DS, Jongepier H, et al. Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol 2003; 112 (4): 717-22
36. Lee JH, Park HS, Park SW, et al. ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics. Clin Exp Allergy 2004; 34 (6): 860-5
37. Werner M, Herbon N, Gohlke H, et al. Asthma is associated with single-nucleotide polymorphisms in ADAM33. Clin Exp Allergy 2004; 34 (1): 26-31
38. Raby BA, Silverman EK, Kwiatkowski AS, et al. ADAM33 polymorphisms and phenotype associations in childhood asthma. J Allergy Clin Immunol 2004; 113 (6): 1071-8
39. Schedel M, Depner M, Schoen C, et al. The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations. Respir Res 2006; 7: 91
40. Wang P, Liu QJ, Li JS, et al. Lack of association between ADAM33 gene and asthma in a Chinese population. Int J Immunogenet 2006; 33 (4): 303-6
41. Blakey J, Halapi E, Bjornsdottir US, et al. Contribution of ADAM33 polimorphisms to the population risk of asthma. Thorax 2005; 60 (4): 274-6
42. Munakata M, Harada Y, Ishida T, et al. Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergol Int 2006; 55 (2): 191-8
43. Janssens AC, Aulchenko YS, Elefante S, et al. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 2006; 8 (7): 395-400
44. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20 (3): 183-94
45. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-409
46. O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Med Res Methodol 2002; 2: 5
47. Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ 2004; 329 (7468): 733-6
48. Dong H, Buxton M. Early assessment of the likely cost-effectiveness of a new technology: a Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care 2006; 22 (2): 191-202
49. Combescure C, Chanez P, Saint Pierre P, et al. Assessment of variations in control of asthma over time. Eur Respir J 2003; 22 (2): 298-304
50. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004; 7 (1): 43-9
51. Cooper NJ, Sutton AJ, Abrams KR, et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004; 13 (3): 203-26
52. Buxton MJ. How much are health-care systems prepared to pay to produce a QALY? Eur J Health Econ 2005; 6 (4): 285-7
53. Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit Care Med 2003; 31 (1 Suppl.): S7-16
54. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
55. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
56. Europe in figures: EuroStat yearbook 2005 [online]. Available from URL: http://epp.eurostat.ec.europa.eu [Accessed 2007 Oct 1]
57. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19 (1): 61-7
58. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111 (6): 1212-8
59. Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003; 21 (1): 116-22
60. Lasserson T, Cates CK, Jones AB, et al. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; (2): CD005309
61. Zika E, Gurwitz D, Ibarreta D. Pharmacogenetics and pharmacogenomics: state of the art and potential socio-economic impacts in the EU. EU Report. Luxembourg: European Commission, 2006
62. Priest VG, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathiotions. prine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomic 2006; 24 (8): 767-81
63. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004; 43 (2): 1156-63
64. Marra CA, Esdaile JM, Anis AH, et al. Practical pharmacogenetics: the cost-effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29 (12): 2507-12
65. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 25 (9): 1069-77
66. Chen S. The cytochrome P4502D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60 (5): 522-34
67. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315: 137-55
68. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116 (5): 325-31
69. Sullivan SD, Buxton M, Andersson LF, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112 (6): 1229-36
70. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-37
71. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23 (7): 639-49
72. Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children. Compr Ophthalmol Update 2006; 7 (1): 31-9
73. Bell CM, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332 (7543): 699-703
74. Brennan A, Akehurst R. Modelling in health economic evaluation: what is its place? What is its value? Pharmacoeconomics 2000; 17 (5): 445-59
75. Gold BD. Asthma and gastroesophageal reflux disease in children: exploring the relationship. J Pediatr 2005; 146 (3 Suppl. 1): S13-20
76. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dematol 2000; 42 (4): 628-32
77. Janssens AC, van Duijn CM. Towards predictive genetic testing of complex diseases. Eur J Epidemiol 2006; 21 (12): 869-70